Viridian TherapeuticsVRDN
VRDN
About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Employees: 94
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
900% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 10 (+9) [Q3]
181% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 16
119% more capital invested
Capital invested by funds: $910M [Q2] → $1.99B (+$1.08B) [Q3]
63% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 40
20% more funds holding
Funds holding: 137 [Q2] → 164 (+27) [Q3]
4.93% more ownership
Funds ownership: 109.6% [Q2] → 114.53% (+4.93%) [Q3]
8% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $12.9M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$27
49%
upside
Avg. target
$37
101%
upside
High target
$47
159%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Needham Serge Belanger 36% 1-year accuracy 47 / 129 met price target | 110%upside $38 | Buy Reiterated | 7 Jan 2025 |
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target | 49%upside $27 | Equal-Weight Downgraded | 19 Dec 2024 |
RBC Capital Gregory Renza 34% 1-year accuracy 29 / 86 met price target | 159%upside $47 | Outperform Maintained | 17 Dec 2024 |
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target | 88%upside $34 | Buy Reiterated | 17 Dec 2024 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and catalysts for 2025. “After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian's President and CEO. “We believe that the positive and better-than-expect.
Positive
Seeking Alpha
1 month ago
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
Positive
Seeking Alpha
1 month ago
Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation
Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to Tepezza with statistically significant effects on diplopia response and diplopia resolution. Veligrotug's results also provide clinical de-risking for next-generation, subcutaneously administered candidate VRDN-003, which I expect to be the key long-term growth driver for the TED franchise.
Positive
Seeking Alpha
1 month ago
Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)
Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved the chances of FDA approval for the company's lead candidate in 2026. Even after the rally in VRDN stock on Monday, the stock remains undervalued given its potential market. The company also has a large cash balance.
Positive
Investors Business Daily
1 month ago
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease appeared first on Investor's Business Daily.
Positive
Reuters
1 month ago
Viridian Therapeutics' eye disorder drug meets late-stage study goal
Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.
Neutral
Business Wire
1 month ago
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). TED is an autoimmune condition characterized.
Neutral
Business Wire
1 month ago
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under “Events and.
Neutral
Business Wire
1 month ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 391,500 shares of the company's common stock to 10 new employees (the “Inducem.
Negative
Zacks Investment Research
2 months ago
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.
Charts implemented using Lightweight Charts™